Molecular Diagnostics and Genomics in Breast Cancer
01.03.2021 - 05.03.2021
Online
$destipo0$
Description
Due to the ongoing Coronavirus (COVID-19) crisis, SPCC has made the difficult decision, in agreement with the chairs and sponsors, to commute the event into a virtual meeting.
We deeply regret having to take this decision but we feel that in the current climate this was the only decision possible.
The new dates will be 1-5 March 2021.
The event attendance will be free of charge, but registration is required on www.oncocorner.net (click here)
Chairs
M.S. Aapro, CH - J. Gligorov, FR
Foreward
The main common feature of cancer cells is their ability to escape to homeostatic regulation mechanisms of living. In a sense giving them immortality, causing in the absence of treatment the death of the organism, which is their origin. The exponential knowledge of the biology of cancer and the phenomenal capacity of synthesis of new treatments and diagnostic tools have opened up the prospect of a precision medicine in oncology that requires regular and frequent updating of our knowledge.
This knowledge concerns both the intrinsic prognosis of the disease, as the prediction value of therapeutic approaches that in fact becomes increasingly “personalized”. This course aims to take stock of current and future tools that help us optimize the care of patients with breast cancer.
Learning Objectives
- Improve breast cancer patients care: value and clinical utility of prediction of CT benefit for early stage breast cancer patients
- Practicing through case discussions
Under the auspices of
Faculty
INVITED FACULTY
Matti Aapro, Clinique de Genolier, Breast Center, Genolier, CH
Fabrice André, Institut Gustave Roussy, Dept. of Medical Oncology, Villejuif, FR
Anna Batistatou, University of Ioannina, Faculty of Medicine, Ioannina, GR
Francesco Cognetti, Istituto Nazionale Tumori Regina Elena, Dipartimento di Oncologia Medica, Roma, IT
Joseph Gligorov, University Cancer Institute APHP.6 Sorbonne University, Breast Cancer Expert Center, Paris, FR
Nadia Harbeck, LMU University Hospital, Breast Centre, Dept. of Obstetrics and Gynaecology, Munich, DE
Christos Markopoulos, National and Kapodistrian University of Athens, Athens, GR
Riccardo Masetti, Università Cattolica di Roma, Oncology Dpt., Roma, IT
Belinda Nedjai, Queen Mary University of London, Wolfson Institute of Preventive Medicine - Centre for Cancer Prevention, London, GB
Frederique Penault-Llorca, Centre Jean Perrin, Anatomopathology Dpt., Clermont-ferrand Cedex, FR
Giancarlo Pruneri, Fondazione IRCCS - Istituto Nazionale dei Tumori, Pathology Dpt., Milano, IT
Pascal Pujol, Centre Hospitalier Universitaire de Montpellier, Genetics Department, Montpellier Cedex5, FR
Elzbieta Senkus, Medical University of Gdansk, Dept. of Oncology and Radiotherapy, Gdansk, PL
Zsuzsanna Varga, University Hospital Zurich, Pathology Dept., Zurich, CH
Mark Verrill, Northern Centre for Cancer Care, Freeman Hospital, Medical Oncology Dept., Newcastle upon Tyne, GB
Marzia Zambon, Europa Donna - The European Breast Cancer Coalition, Milan, IT
General information
ORGANISING SECRETARIAT
Sharing Progress in Cancer Care
Piazza Indipendenza, 2
6500 Bellinzona – Switzerland
Luis Carvalho
Luis.carvalho@spcc.net - Tel: +41 91 820 09 58
CME Accreditation and Certificates
Participants will be issued a certificate of attendance (minimum attendance: 75% of the entire course). An online evaluation questionnaire and learning assessment test will need to be completed in order to get the certificate that will be issued by email.
Application for CME recognition has been submitted to the Accreditation Council of Oncology in Europe (ACOE) and 8 CME credits have been granted to this event. The American Medical Association (AMA) and the Accreditation Council for Continuous Medical Education (ACCME) designate this type of educational activity for a maximum of 1 AMA PRA category 1 credits per hour of activity.
ACKNOWLEDGEMENTS
Sharing Progress in Cancer Care wishes to extend its appreciation to Daiichi Sankyo, Exact Sciences and Pfizer for having granted their participation and support to the Course.
Registration
The event attendance will be free of charge, but registration is required on www.oncocorner.net
Programme
01 March | ||
15:45 | Welcome and introduction Matti Aapro, CH - Joseph Gligorov, FR | |
15:50 | Optimize patient management in breast cancer: guiding adjuvant treatment decisions Mark Verrill, UK | |
16:05 | Clinical utility of multigene assays in early breast cancer | |
16:05 | Predictive tests Christos Markopoulos, GR | |
16:15 | Prognostic tests Francesco Cognetti, IT | |
16:25 | Who to test with multigene assay: treatment algorithms – specific patient profiles (lobular; premenopausal CT decisions) | |
16:25 | Clinical perspective Ulrike Nitz, DE | |
16:35 | Next Generation Sequencing. The pathology perspective. Anna Batistatou, GR | |
17:00 | Discussion and Q&A | |
02 March | ||
15:45 | Welcome and introduction | |
15:50 | Roundtable: Evidence based assessment of diagnostic tests: criteria for a health technology assessment – why outcomes of HTA decisions can be different…? | |
15:50 | The French rationale Pascal Pujol, FR | |
16:00 | Why NICE accepted? Mark Verrill, UK | |
16:10 | Why German authorities accepted? Ulrike Nitz, DE | |
16:20 | The essential pathology testing needed for breast cancer, quality control Anna Batistatou, GR | |
16:40 | What tests to ask for and what clinical implications in "TRIPLE NEGATIVE" BrCa Nadia Harbeck, DE | |
16:55 | The patient advocacy perspective Marzia Zambon, IT | |
17:25 | Discussion and Q&A | |
03 March | ||
17:15 | Welcome and introduction | |
17:20 | Group session: Patient Case discussion on multigene assays in early breast cancer: who to test and how to deal with the results? | |
17:20 | Goup 1 Joseph Gligorov, FR - Riccardo Masetti, IT - Elzbieta Senkus, PL - Zsuzsanna Varga, CH | |
Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk | ||
Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk | ||
Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk | ||
Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk | ||
17:20 | Group 2 Matti Aapro, CH - Christos Markopoulos, GR - Miguel Martin, ES - Giancarlo Pruneri, IT | |
Case 1: 1 patient 29 years HR+, HER2- pN0 with low-clinical risk | ||
Case 2: 1 patient 73 years HR+, HER2- pN1 with high-clinical risk | ||
Case 3: 1 patient 45 years HR+, HER2- pN0 with intermediate-clinical risk | ||
Case 4: 1 patient 55 years HR+, HER2- pN0 with intermediate-clinical risk | ||
18:35 | Panellists case discussion summary and Q&A | |
04 March | ||
15:45 | Advanced breast cancer (PART1) | |
15:45 | Welcome and introduction | |
15:50 | DNA Methylation Romano Danesi, IT | |
16:10 | NGS impact or not in breast cancer Fabrice André, FR | |
16:30 | Alpelisib what to test | |
16:30 | Clinical positioning Elzbieta Senkus, PL | |
16:45 | What to test Frederique Penault-Llorca, FR | |
17:15 | Discussion and Q&A | |
05 March | ||
15:45 | Advanced breast cancer (PART2) | |
15:45 | Welcome and introduction | |
15:50 | Parp inhibitors what to test | |
15:50 | Test Pascal Pujol, FR | |
16:05 | Clinical implication Ulrike Nitz, DE | |
16:20 | Immunotherapy: what to test | |
16:20 | Test Frederique Penault-Llorca, FR | |
16:35 | Clinical implication Francesco Cognetti, IT | |
16:50 | HER-2 alterations not defined as ASCO CAP HER-2 positivity | |
16:50 | Test Frederique Penault-Llorca, FR | |
17:05 | Clinical implication Joseph Gligorov, FR | |
17:35 | Discussion and Q&A | |
18:05 | Closure |